Yartemlea (Narsoplimab-wuug)

Yartemlea (Narsoplimab-wuug) is a MASP-2 inhibitor approved for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

Recommended Dosage:
The recommended dosage of Yartemlea for adults and pediatric patients aged 2 years and older with TA-TMA depends on body weight.
For patients weighing 50 kg or more, the recommended dose is 370 mg, administered as an intravenous (IV) infusion over 30 minutes once weekly. If there is inadequate improvement in TA-TMA signs and symptoms, the dosing frequency may be increased to twice weekly at the treating physician’s discretion.
For patients weighing less than 50 kg, the recommended dose is 4 mg per kilogram of body weight, given as an IV infusion over 30 minutes once weekly. If the response is insufficient, the physician may increase the frequency to twice weekly.

If a dose is missed, it should be administered as soon as possible. Afterward, dosing should continue according to the regular schedule.

• Yartemlea Injection may increase the risk of serious infections by affecting the immune system. Patients should be monitored for fever, cough, fatigue, or other infection symptoms. Treatment should be paused if a severe infection develops, and medical attention must be sought immediately.
• Yartemlea Injection may cause harm to an unborn baby. Women who are pregnant or planning pregnancy should consult their doctor before starting treatment. Effective contraception is recommended during therapy and for the advised period after the final dose.
• It is not known whether Yartemlea Injection passes into breast milk. Because of potential risk to the infant, breastfeeding is generally not recommended during treatment and for a certain period after the last dose. Discuss feeding options with your healthcare provider.
• The safety and effectiveness of Yartemlea Injection in children have not been fully established. Use in pediatric patients should be based on specialist evaluation. Close monitoring is required if prescribed, and benefits must clearly outweigh potential risks.

What documents are required to import YARTEMLEA to India?

YARTEMLEA (narsoplimab-wuug) injections can be imported by patients or government hospitals in the name of the patients only.

• The following documentation is required to import the product:
• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is YARTEMLEA available in India?

YARTEMLEA (narsoplimab-wuug injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On the availability of Yartemlea in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
  Yartemlea price in India.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

YARTEMLEA can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of YARTEMLEA (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91 98104 69557 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Yartemlea cost in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source YARTEMLEA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Yartemlea®?

Narsoplimab-wuug is the Generic Name for the trade name drug Yartemlea®.

What is the Manufacturer’s Name of Yartemlea®?

Yartemlea® is manufactured by Omeros Corporation.

Is Yartemlea approved by the FDA?

Yes. Yartemlea is approved by the FDA. Date of first approval: December 23, 2025.

What is the dosage and form of Yartemlea® supplied?

Yartemlea is supplied as an Injection: 370 mg/2 mL (185 mg/mL) in a single-dose vial for intravenous use.

What are the most common side effects of Yartemlea® 370 mg/2 mL (185 mg/mL) Injections?

The most commonly reported side effects of Yartemlea® are viral infections, nausea, sepsis, vomiting, hemorrhage, diarrhea, neutropenia, pyrexia, fatigue, and hypokalemia.

How does Yartemlea Import in India work?

Yartemlea Import in India is possible through the Named Patient Program. This means the medicine can be imported for a specific patient with a valid doctor’s prescription. Indian Pharma Network helps manage the complete process, including approvals and delivery, making sure the medicine reaches the patient safely and legally.

Who is a reliable Yartemlea supplier in India?

Indian Pharma Network is a trusted Yartemlea supplier in India, facilitating compliant access through global sourcing channels and structured documentation support for eligible patients under applicable regulatory provisions.

How much does Yartemlea® 370 mg/2 mL (185 mg/mL) injection cost in India?

Yartemlea® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Yartemlea prices may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Yartemlea cost in India, please call/WhatsApp +91 98104 69557 or send an email to info@indianpharmanetwork.in.

Can Yartemlea® 370 mg/2 mL (185 mg/mL) injection be available in SAARC countries?

Apart from Gulf countries, Yartemlea® 370 mg/2 mL (185 mg/mL) can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Yartemlea® injection in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Yartemlea® 370 mg/2 mL (185 mg/mL) Injections online in India?

Yes, one can buy Yartemlea in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not yet registered or available in their country. We can help facilitate the supply of Yartemlea® injection through legal channels.

Who is an authorized Yartemlea importer in India?

Indian Pharma Network acts as a Yartemlea importer in India, assisting with Named Patient import processes, regulatory documentation, and compliant international procurement for patients requiring this therapy.

What are the storage conditions of Yartemlea® 370 mg/2 mL (185 mg/mL) Injections?

Store the vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of use. It is not advisable to freeze or shake the vials. Avoid using beyond the expiration date mentioned on the carton.